Potent and selective PPARγ agonist; antidiabetic agent
Rosiglitazone is a potent and selective PPARγ agonist (EC50 = 60 nM); exhibits no activity at PPARα and PPARβ. Promotes differentiation of pluripotent C3H10T1/2 stem cells into adipocytes. Also promotes differentiation of urothelial organoids in combination with Erlotinib (Cat. No. 7194). Exhibits antihyperglycemic activity in diabetic
ob/ob
mouse model. Antidiabetic agent.
| Marque | Tocris Bioscience |
|---|---|
| Réf. B-LABO | BL-RE-126371 |
| Réf. fabricant | 18710518 |
| Nom chimique ou matériau | 5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione |
| CAS | 122320-73-4 |
| Synonyme | BRL 49653 |
| Quantité | 50 mg |
| Cible | PPAR gamma Receptor Agonists |
| Formule moléculaire | C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S |
| Poids de la formule | 357.43 |
| Pureté | 98% |
